| Name | Title | Contact Details |
|---|
CRB is a Oreland, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Karalex Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.